



ASX ANNOUNCEMENT

24 NOVEMBER 2023

## PROGRAM UPDATE WEBINAR WITH CHIMERIC EXECUTIVE TEAM

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce it will host a webinar for shareholders, investors and other interested parties whereby the Chimeric executive team will present an update on and discuss the Company’s portfolio of assets.

When: 11:30am AEDT, Tuesday 28 November 2023

Register at: [https://us02web.zoom.us/webinar/register/WN\\_1pHYeOH2QQSAwpw\\_KsOdYg](https://us02web.zoom.us/webinar/register/WN_1pHYeOH2QQSAwpw_KsOdYg)

Who:

- Jennifer Chow – CEO and Managing Director
- Dr Jason B. Litten – Chief Medical Officer
- Dr Eliot Bourk – Chief Business Officer and Head of External Innovation
- Kelly Thornburg – Vice President, Head of Technical Operations
- Dr Stephanie Astrow – Vice President, Head of Translational Development

Upon registering attendees will receive an email containing information about joining the webinar. A recording will be available at the above link soon after the conclusion of the live session, with the replay to also be made available via Chimeric’s website and social media channels.

An opportunity to ask questions will also be provided. Questions can be sent in advance of the webinar to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

## ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2023.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients



with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

## CONTACT

### Investors

Jennifer Chow

Chief Executive Officer and Managing Director  
Chimeric Therapeutics

T: + 1 9087238387

E: [jchow@chimerictherapeutics.com](mailto:jchow@chimerictherapeutics.com)

W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Paul Hopper

Executive Chairman

Chimeric Therapeutics

T: + 61 406 671 515

E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

### Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)